Top

International Ophthalmology

Published in:

01-01-2019 | Original Paper

Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion

Authors: Francesco Pichi, Ahmed Mohammed Elbarky, Tarek Roshdy Elhamaky

Published in: International Ophthalmology | Issue 1/2019

Abstract

Purpose

To compare the efficacy of a modified PRN treatment regimen (“treat and monitor”) of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.

Methods

Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a “treat and monitor” treatment regimen with monthly follow-up for 12 months. Primary outcome measures included mean change in best corrected visual acuity (BCVA) and central foveal thickness (CFT) at month 12 compared to baseline.

Results

At 12 months follow-up, the mean BCVA improved from 0.58 ± 0.13 to 0.20 ± 0.15 logMAR (P = 0.0003) in the aflibercept group (mean injections 2.6 ± 1.51) and from 0.52 ± 0.11 to 0.21 ± 0.1 logMAR (P = 0.0002) in the ranibizumab group (mean injections 2.8 ± 1.78). No statistical difference between the two groups in terms of the visual acuity gains in eyes with macular edema secondary to non-ischemic BRVO treated with either aflibercept or ranibizumab was observed. Mean CFT reduced from 498 ± 46 to 204 ± 23 µm (P < 0.0001) in the aflibercept group and from 488 ± 31 to 212 ± 29 µm (P < 0.0001) in the ranibizumab group.

Conclusion

“Treat and monitor” regimen is a real-life effective strategy in improving visual acuity after macular edema from branch vein occlusion and in reducing the number of injections.

Rogers S, McIntosh RL, Cheung N et al (2010) International eye disease consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313–319CrossRefPubMedPubMedCentral

Klein R, Moss SE, Meuer SM, Klein BE (2008) The15-year cumulative incidence of retinal vein occlusion: the beaver dam eye study. Arch Ophthalmol 126:513–518CrossRefPubMed

McIntosh RL, Rogers SL, Lim L et al (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117:1113–1123CrossRefPubMed

Bajor A, Pielen A, Danzmann L (2017) Retinal vein occlusion - which treatment when? Klin Monbl Augenheilkd 234(10):1259–1265CrossRefPubMed

Lee WJ, Kang MH, Seong M, Cho HY (2012) Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular edema due to branch retinal vein occlusion. Br J Ophthalmol 96(11):1426–1430CrossRefPubMed

Noma H, Funatsu H, Yamasakietal M (2008) Aqueous humor levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22(1):42–48CrossRefPubMed

Hikichi T, Higuchi M, Matsushita T et al (2014) Two-year outcomes of intravitreal bevacizumab therapy for macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 98(2):195–199CrossRefPubMed

Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-Schmidt KU, Jaissle GB (2013) Grid laser photocoagulation for macular edema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol 97(2):215–219CrossRefPubMed

Battaglia Parodi M, Saviano S, Ravalico G (1999) Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 237:1024–1027CrossRefPubMed

10.

Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary endpoint results of a phase III study. Ophthalmology 117:1124–1133CrossRefPubMed

11.

Genentech Press Release (2012) FDA approves Lucentis^® (Ranibizumab injection) for the treatment of macular edema following retinal vein occlusion

12.

Ahn SJ, Ahn J, Woo SJ, Park KH (2013) Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary tobranchretinalveinocclusion. BioMed Res Int 2013, Article ID 209735

13.

Hayashi A, Yunoki T, Miyakoshi A, Mitarai K, Fujino T, Yanagisawa S (2011) Intravitreal injection of bevacizumab combined with macular grid laser photocoagulation for macular edema in branch retinal vein occlusion. Jpn J Ophthalmol 55(6):625–631CrossRefPubMed

14.

Fauser S, Schwabecker S, Muether PS (2014) Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol 158(3):532–536CrossRefPubMed

15.

Campochiaro PA, Clark WL, Boyer DS et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122(3):538–544CrossRefPubMed

16.

Klettner AI, Recber M, Roider J (2014) Comparison of the efficacy of aflibercept, ranibizumab and bevacizumab in an RPE/choroid organ culture. Graefes Arch Clin Exp Ophthalmol 252:1593–1598CrossRefPubMed

17.

Pielen A et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS ONE 8(10):e78538CrossRefPubMedPubMedCentral

18.

Pielen A et al (2015) Ranibizumab for branch retinal vein occlusion associated macular edema study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol 93(1):e29–e37CrossRefPubMed

19.

Campochiaro PA, Heier JS, Feiner L et al (2010) BRAVO investigators ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102.e1–1112.e1

20.

21.

Michels S, Stephan A, Magdalena AW (2016) Branch retinal vein occlusion-update on treatment options. Eur Ophthalmic Rev 10(1):25–26CrossRef

22.

Patrick O, Dilraj S, Grewaland S (2016) Role of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trials. Clin Ophthalmol 10(411–418):22

23.

Noma H, Funatsu H, Yamasaki M et al (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 22:42–48CrossRef

24.

Ehlers JP, Fekrat S (2011) Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 56:281–299CrossRefPubMed

25.

Hahn P, Fekrat S (2012) Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 23:175–181CrossRefPubMed

26.

Regnier SA, Larsen M, Bezlyak V, Allen F (2015) Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open 5(6):e007527CrossRefPubMedPubMedCentral

27.

Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH (2015) A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no. 1. Br J Ophthalmol 99(7):954–959CrossRefPubMed

28.

Preti RC et al (2012) Single intravitreal bevacizumab injection effects on contrast sensitivity in macular edema from branch retinal vein occlusion. Arq Bras Oftalmol São Paulo 75(1):29–32CrossRef

29.

Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594–1602CrossRefPubMed

30.

Sakanishi Y, Ouchi A, Ito R et al (2016) Six months’ outcomes in patients with macular edema due to retinal vein occlusion treated with ranibizumab. Nippon Ganka Gakkai Zasshi 120(1):28–34PubMed

31.

Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH (2015) A randomized, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no. 1. Br J Ophthalmol 99(7):954–959CrossRefPubMed

32.

Jai-Kang W, Tzu-Lun H, Pei-Yuan S et al (2015) Intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion in Chinese patients. Eye Sci 30:63–66

33.

Higashiyama T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ohji M (2013) Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol 91(4):318–324CrossRefPubMed

34.

Bakri SJ (2015) Clinical trials: a need to better define the control group as current standard of care. Ophthalmology 122:443–444CrossRefPubMed

Title: Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion
Authors: Francesco Pichi
Ahmed Mohammed Elbarky
Tarek Roshdy Elhamaky
Publication date: 01-01-2019
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 1/2019
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-017-0798-6

At a glance: The STEP trials

Springer Medicine

Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Comparison of trypan blue and Brilliant Blue G for staining of the anterior lens capsule during cataract surgery: short-term results

Equine pericardium for tectonic globe repair

Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients

Strabismus surgery for diplopia in chronic progressive external ophthalmoplegia

Simplified approach of Gokyigit’s technique for complete cranial nerve third palsy

Correction to: Primary vitrectomy with short-term silicone oil tamponade for uncomplicated rhegmatogenous retinal detachment